IN2014CN02805A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02805A
IN2014CN02805A IN2805CHN2014A IN2014CN02805A IN 2014CN02805 A IN2014CN02805 A IN 2014CN02805A IN 2805CHN2014 A IN2805CHN2014 A IN 2805CHN2014A IN 2014CN02805 A IN2014CN02805 A IN 2014CN02805A
Authority
IN
India
Prior art keywords
compounds
medicaments
variables
inhibitors
formula
Prior art date
Application number
Inventor
Michael J Orwat
Donald J P Pinto
Ii Leon M Smith
Shefali Srivastava
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IN2014CN02805A publication Critical patent/IN2014CN02805A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides compounds of Formula (I) or stereoisomers pharmaceutically acceptable salts thereof wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
IN2805CHN2014 2011-10-14 2012-10-12 IN2014CN02805A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161547301P 2011-10-14 2011-10-14
PCT/US2012/059932 WO2013056034A1 (en) 2011-10-14 2012-10-12 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors

Publications (1)

Publication Number Publication Date
IN2014CN02805A true IN2014CN02805A (en) 2015-07-03

Family

ID=47116434

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2805CHN2014 IN2014CN02805A (en) 2011-10-14 2012-10-12

Country Status (7)

Country Link
US (1) US9079929B2 (en)
EP (1) EP2766347B1 (en)
JP (1) JP6033318B2 (en)
CN (1) CN103987696B (en)
ES (1) ES2579832T3 (en)
IN (1) IN2014CN02805A (en)
WO (1) WO2013056034A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101901545B1 (en) 2010-02-11 2018-09-21 브리스톨-마이어스 스큅 컴퍼니 Macrocycles as factor xia inhibitors
TW201311689A (en) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocycles as factor XIa inhibitors
TW201319068A (en) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9079929B2 (en) 2011-10-14 2015-07-14 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
RS56168B1 (en) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014014050A1 (en) 2012-07-19 2014-01-23 大日本住友製薬株式会社 1-(cycloalkyl-carbonyl)proline derivative
EA025392B1 (en) 2012-08-03 2016-12-30 Бристол-Маерс Сквибб Компани DIHYDROPYRIDONE P1 AS FACTOR XIa INHIBITORS
PT2880026T (en) 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
EP2906541B1 (en) * 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CA2888100A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
PL2964023T3 (en) * 2013-03-05 2020-01-31 Bayer Cropscience Aktiengesellschaft Use of n-(2-methoxybenzoyl)-4-[methylaminocarbonyl)amino]benzenesulfonamide in combination with an insecticide or fungicide for improving plant yield
EP2978751B1 (en) * 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
US20160257668A1 (en) 2013-10-07 2016-09-08 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
US20170002006A1 (en) 2014-01-31 2017-01-05 Bristol-Myers Squibb Company Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
EP3104703B1 (en) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
WO2015164308A1 (en) 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EP3164388A1 (en) 2014-07-01 2017-05-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds and their use as retinoid-related orphan receptor (ror) gamma-t inhibitors
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
US10081623B2 (en) 2014-09-04 2018-09-25 Bristol-Myers Squibb Company Diamide macrocycles that are FXIa inhibitors
ES2716417T3 (en) 2014-09-24 2019-06-12 Bayer Pharma AG Derivatives of oxopyridine substituted with anti-inflammatory and antithrombotic action
US10167280B2 (en) 2014-09-24 2019-01-01 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
ES2762987T3 (en) 2015-06-19 2020-05-26 Bristol Myers Squibb Co Diamide macrocycles as factor XIA inhibitors
JO3703B1 (en) 2015-07-09 2021-01-31 Bayer Pharma AG Substituted oxopyridine derivatives
WO2017019819A1 (en) 2015-07-29 2017-02-02 Bristol-Myers Squibb Company Factor xia macrocyclic inhibitors bearing alkyl or cycloalkyl p2' moieties
ES2871111T3 (en) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Macrocyclic factor XIa inhibitors containing a non-aromatic P2 'group
US10336730B2 (en) 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors
AU2016344476B2 (en) 2015-10-29 2020-08-13 Merck Sharp & Dohme Llc Factor XIa inhibitors
US10344039B2 (en) 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
WO2017123518A1 (en) * 2016-01-11 2017-07-20 The Rockefeller University Aminotriazole immunomodulators for treating autoimmune diseases
US11078195B2 (en) * 2016-03-17 2021-08-03 Checkmate Therapeutics Inc. Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
EP3500556B1 (en) 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Pyridine-1-oxide derivatives and their use as factor xia inhibitors
WO2018041122A1 (en) 2016-08-31 2018-03-08 江苏恒瑞医药股份有限公司 Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
CN109721539B (en) * 2017-10-27 2021-07-09 天津药物研究院有限公司 Pyrazole amide derivative and preparation method and application thereof
CN109867660A (en) * 2017-12-01 2019-06-11 四川科伦博泰生物医药股份有限公司 Tetrahydroisoquinoline amide compound and its medicinal usage containing quaternary ammonium ion
CN111655686B (en) * 2018-03-28 2024-02-09 四川科伦博泰生物医药股份有限公司 Tetrahydroisoquinoline derivative and preparation method and application thereof
EP3976027A4 (en) * 2019-05-30 2023-01-11 Merck Sharp & Dohme LLC Factor xi activation inhibitors
US20230147170A1 (en) * 2020-04-01 2023-05-11 Merck Sharp & Dohme Llc Factor xi activation inhibitors
US20230167085A1 (en) * 2020-05-12 2023-06-01 Merck Sharp & Dohme Llc Factor xi activation inhibitors
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525186A (en) 1967-03-29 1968-05-17 Roussel Uclaf New penicillins and method of preparation
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
DE4034829A1 (en) 1990-11-02 1992-05-07 Merck Patent Gmbh CYCLOPEPTIDE
JP3190431B2 (en) 1991-07-01 2001-07-23 三菱化学株式会社 Ketone derivatives
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU717298B2 (en) 1996-04-03 2000-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO1999047545A2 (en) 1998-03-19 1999-09-23 Vertex Pharmaceuticals Incorporated Inhibitors of caspases
HUP0102514A3 (en) 1998-05-26 2002-03-28 Warner Lambert Co Pyrido-pyrimidin and pyrimido-pyrimidin derivatives as inhibitors of cellular proliferation and pharmaceutical compositions thereof
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
AU3043100A (en) 1999-01-02 2000-07-24 Aventis Pharma Deutschland Gmbh Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
BR0009678A (en) 1999-04-09 2002-01-22 Basf Ag Compounds, pharmaceutical composition, and use of compounds
AU5413600A (en) 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
BR0110638A (en) 2000-05-11 2003-03-25 Bristol Myers Squibb Co Tetrahydroisoquinoline analogues useful as growth hormone secretagogues
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
AR035216A1 (en) 2000-12-01 2004-05-05 Astrazeneca Ab MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS
GEP20074098B (en) 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2003041641A2 (en) * 2001-11-09 2003-05-22 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (en) * 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド Aryl and heteroaryl compounds, compositions and methods of use
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP2457895A1 (en) 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
EP1841504B1 (en) 2005-01-13 2014-11-19 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
CN101198591B (en) 2005-06-17 2011-06-22 巴斯福股份公司 Process of producing bleach boosters
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EA014245B1 (en) 2005-12-14 2010-10-29 Бристол-Маерс Сквибб Компани Arylpropionamide, arylacrylamide, arylpropynamide or arylmethylurea analogs as factor xia inhibitors
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
PT2061465E (en) 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
WO2008076805A2 (en) 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
CL2008001724A1 (en) 2007-06-13 2008-08-08 Bristol Myers Squibb Co COMPOUNDS DERIVED FROM DIPEPTID ANALOGS, INHIBITORS OF THE COAGULATION FACTOR; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF A THROMBOEMBOLIC DISORDER, MYOCARDIUM INFAR, THROMBOSIS, ATE
ES2380648T3 (en) 2008-03-13 2012-05-17 Bristol-Myers Squibb Company Pyridazine derivatives as XIA factor inhibitors
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
KR101901545B1 (en) 2010-02-11 2018-09-21 브리스톨-마이어스 스큅 컴퍼니 Macrocycles as factor xia inhibitors
WO2013009527A2 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Factor ixa inhibitors
TW201311689A (en) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocycles as factor XIa inhibitors
TW201319068A (en) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
RS56168B1 (en) 2011-10-14 2017-11-30 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9079929B2 (en) 2011-10-14 2015-07-14 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
ES2765891T3 (en) 2011-12-21 2020-06-11 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US20140350034A1 (en) 2012-01-27 2014-11-27 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (en) 2012-02-08 2015-04-30 大日本住友製薬株式会社 Three substituted proline derivative
KR102060376B1 (en) 2012-05-10 2019-12-30 바이엘 파마 악티엔게젤샤프트 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014014050A1 (en) 2012-07-19 2014-01-23 大日本住友製薬株式会社 1-(cycloalkyl-carbonyl)proline derivative
PT2880026T (en) 2012-08-03 2017-05-03 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
EA025392B1 (en) 2012-08-03 2016-12-30 Бристол-Маерс Сквибб Компани DIHYDROPYRIDONE P1 AS FACTOR XIa INHIBITORS

Also Published As

Publication number Publication date
US20140274960A1 (en) 2014-09-18
CN103987696A (en) 2014-08-13
WO2013056034A1 (en) 2013-04-18
JP2014530240A (en) 2014-11-17
JP6033318B2 (en) 2016-11-30
EP2766347A1 (en) 2014-08-20
CN103987696B (en) 2016-12-21
EP2766347B1 (en) 2016-05-04
US9079929B2 (en) 2015-07-14
ES2579832T3 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
IN2014CN02805A (en)
IN2014CN02806A (en)
TN2014000155A1 (en) Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
MX2015000892A (en) Dihydropyridone p1 as factor xia inhibitors.
MX2015000919A (en) Dihydropyridone p1 as factor xia inhibitors.
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
UA108442C2 (en) Indazol
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
IN2014MN02658A (en)
IN2015DN01156A (en)
IN2015DN00598A (en)
NZ708382A (en) Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents
MY162936A (en) Macrocycles as factor xia inhibitors
IN2014MN02657A (en)
AU2012214029A8 (en) Rorgammat inhibitors
UA111382C2 (en) Protein kinase inhibitors
MX2014014229A (en) Substituted pyrrolidine-2-carboxamides.
MX2016000675A (en) Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof.
IN2015DN00185A (en)
IN2014CN03803A (en)
JO3115B1 (en) Pyridazinone Compounds and Their Use as DAAO Inhibitors
IN2014DN06869A (en)
GB201209587D0 (en) Therapeutic compounds
MX362879B (en) Novel uses.